CytoDyn Inc.
CYDY
$0.215
-$0.0208-8.82%
| Weiss Ratings | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.39 | |||
| Price History | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -19.78% | |||
| 30-Day Total Return | 3.46% | |||
| 60-Day Total Return | 67.97% | |||
| 90-Day Total Return | 63.75% | |||
| Year to Date Total Return | 84.55% | |||
| 1-Year Total Return | 22.16% | |||
| 2-Year Total Return | -43.42% | |||
| 3-Year Total Return | -45.50% | |||
| 5-Year Total Return | -78.45% | |||
| 52-Week High % Change | -52.31% | |||
| 52-Week Low % Change | 128.76% | |||
| Price | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.49 | |||
| 52-Week Low Price | $0.10 | |||
| 52-Week Low Price (Date) | Nov 29, 2024 | |||
| 52-Week High Price (Date) | Feb 24, 2025 | |||
| Valuation | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 289.68M | |||
| Enterprise Value | 297.08M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -72.54% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -3.23 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.22 | |||
| Enterprise Value/EBITDA (TTM) | -18.25 | |||
| Enterprise Value/EBIT | -18.22 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.22B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 360 980 8524 | |||
| Address | 1111 Main Street Vancouver, WA 98660 | |||
| Website | www.cytodyn.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -59.73% | |||
| Return on Equity | -- | |||
| Income Statement | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -16.28M | |||
| EBIT (TTM) | -16.30M | |||
| Net Income (TTM) | -14.25M | |||
| Net Income Avl. to Common (TTM) | -14.25M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 50.14% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | 59.62% | |||
| Balance Sheet | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 21.34M | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 24.63M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -89.39M | |||
| Current Ratio (Q) | 0.349 | |||
| Book Value Per Share (Q) | -$0.07 | |||
| Total Assets (Q) | 24.88M | |||
| Total Current Liabilities (Q) | 70.63M | |||
| Total Debt (Q) | 28.74M | |||
| Total Liabilities (Q) | 114.27M | |||
| Total Common Equity (Q) | -89.39M | |||
| Cash Flow | CYDY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 16.74M | |||
| Net Change in Cash (TTM) | 14.61M | |||
| Levered Free Cash Flow (TTM) | -54.20M | |||
| Cash from Operations (TTM) | -2.13M | |||
